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84164 | RSC Adv., 2015, 5, 84164–8417l high-throughput AlphaLISA assay
to quantify plasma NHERF1 as a non-small cell lung
cancer biomarker†
Guifang Du,‡ab Xiaomei Yang,‡ab Mu Hu,bc Chengcheng Hao,ab Yanan Gu,ab
Xiuyi Zhi,bc Wen G. Jiang,abd Junqi He*ab and Shan Cheng*ab
NHERF1 might play a signiﬁcant role in biological processes including oncogenic transformation and
metastasis. Owing to the lack of highly sensitive and quantitative methods of NHERF1 in human plasma,
there have been few reports on the plasma levels of NHERF1 and its correlation with cancer. Here,
a novel ampliﬁed luminescent proximity homogeneous immunoassay (AlphaLISA) has been developed
and validated for the quantiﬁcation of NHERF1 in human plasma. This assay was based on an
AlphaScreen detection technique with two diﬀerent anti-NHERF1 antibodies coupled to donor and
acceptor beads, respectively. The developed AlphaLISA assay was further optimized and validated in
terms of linearity, limit of detection (LOD), limit of quantiﬁcation (LOQ), precision, recovery, selectivity
and interferences. The linear range of NHERF1 in human plasma was 5.00–100 ng mL1, with an LOD of
2.00 ng mL1. This AlphaLISA assay has been successfully applied to the quantiﬁcation of NHERF1 in the
plasma from 75 patients with non-small cell lung cancer (NSCLC). The levels of NHERF1 protein in
plasma from patients with NSCLC were signiﬁcantly higher than those in the healthy group (p ¼ 0.0004).
Based on the evaluation of the ROC curves, measuring the content of NHERF1 in human plasma could
provide a potential diagnostic tool for NSCLC.1. Introduction
Early diagnosis of cancer, the leading cause of death globally, is
the key to treatment and long term survival of patients. Despite
the progress in imaging techniques, such as radiographs and
computerized tomography, cheap and reliable serum based
methods which rely on tumor markers for cancer screening and
diagnosis remains a challenge.1,2 Detection of cancer at an early
disease stage is critical for successful clinical therapy, an
improved prognosis, and increased survival rate. One of the
current focuses in the area of cancer is the development of
blood based tests for cancer screening and diagnosis.1
Na+/H+ exchanger regulatory factor 1 (NHERF1; also known
as ezrin–radixin–moesin-binding phosphoprotein 50, EBP50) is
a 358-residue protein composed of two tandem PDZ domainsar Biology, Capital Medical University,
u.edu.cn; jq_he@ccmu.edu.cn
sis Research, Capital Medical University,
g Xuanwu Hospital, Capital Medical
ive, Cardiﬀ University School of Medicine,
tion (ESI) available. See DOI:
paper.
1and a C-terminal ezrin-binding region3,4 (Fig. 1a). It functions as
a molecular scaﬀold that coordinates the interaction of trans-
membrane proteins and cytosolic second messenger cascades.
NHERF1 and its associated proteins are involved in cancer and
cancer progression, such as phosphatase and tensin homologue
(PTEN),5 neurobromatosis tumor suppressors,6 b-catenin,7
platelet-derived growth factor receptor8 and epidermal growth
factor receptor.9,10 These functions have raised some signicant
interests in NHERF1 which has been explored as a potentially
attractive target for both diagnosis and treatment in cancer.3
Abnormal expression of NHERF1 has been found in several
types of human tumors, including schwannoma, hepatocellular
carcinoma, glioblastoma,11 especially in colorecal12 and breast
cancer.3 Studies utilizing western blot (WB) analysis and
immunohistochemistry (IHC) of a series of tumors13 and
contiguous non-involved tissues from the same patient have
clearly demonstrated that NHERF1 is highly over-expressed in
tumor tissues14 and that the over-expression is associated with
increasingly aggressive clinical characteristics of the tumors
and with poor prognosis of the patients.13,15 A heterogeneous
and diﬀerent distribution of NHERF1 expression was also
observed in normal breast and colon, in situ carcinoma and
invasive tumors as well as metastatic tumors.12,16 Indeed, cyto-
plasmic NHERF1 expression progressively increased in tumor
cells from carcinoma in situ to invasive and metastatic tissues,
and this increased cytoplasmic expression was paralleled byThis journal is © The Royal Society of Chemistry 2015
Fig. 1 Principle of AlphaLISA for the detection of NHERF1. (a)
Molecular structure of NHERF1 showing selected interacting proteins
above each domain; (b) detection of NHERF1 occurs via two anti-
NHERF1 antibodies (immunizing aa 128–249 or 310) coupled to donor
and acceptor beads respectively. Irradiation of the captured reaction
products triggers an energy transfer leading to light emission
proportional to the content of NHERF1 in plasma.
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View Article Onlinea progressive and signicant decrease in membranous NHERF1
expression.17 Overall, these data have led to suggestions that
NHERF1 may be useful as a marker of clinical relevance in
cancer patients.3 However, no study have reported the changes
of NHERF1 in plasma correlated with cancer, arguably due to
lack of highly sensitive and quantitative methods for the iden-
tication of NHERF1 in human plasma, a highly challenging
task. Because of these intrinsic limitations, alternative innova-
tive assays that are robust, cost-eﬀective, and easy to automate
with high-throughput are urgently required for clinical appli-
cations. The AlphaLISA (amplied luminescent proximity
homogeneous immunoassay) immunoassay platform has
gained popularity over recent years and has been seen as an
enhanced solution to enzyme-linked immunoassay (ELISA)
tests.18–20 AlphaLISA has been developed from luminescent
oxygen channeling immunoassay (LOCI) technique, in which
the proximity of donor beads and acceptor beads cause singlet
oxygen transferred, emitting light through chem-
iluminescence21 (Fig. 1b). The long singlet oxygen migration
distance allows the energy transfer mechanism to go up to200This journal is © The Royal Society of Chemistry 2015nm, facilitating exible and sensitive homogeneous immuno-
assays. This technique has been successfully applied to the
detection of soluble proteins and particulate antigens.22,23 Per-
kin-Elmer's bead-based chemiluminescent no-wash assay has
high sensitivity, wide dynamic range and robust performance
that compares advantage with conventional ELISA.18
The aim of this study was to develop and validate a novel
high-throughput AlphaLISA assay for the quantication of
NHERF1 in human plasma. Subsequently, it was intended to
investigate its applicability by analyzing the levels of NHERF1 in
the plasma of patients with NSCLC. The AlphaLISA assay may
subsequently be used for the detection of NHERF1 for cancer
patients.2. Experimental
2.1 Chemicals and reagents
Puried anti-NHERF1 mouse antibody (material no. 611161)
was obtained from BD Company (Franklin Lake, NJ, USA) and
anti-NHERF1 rabbit antibody (material no. 3394) was obtained
from Cell Signaling Technologies (Boston, MA, USA). Anti-
mouse IgG-coated donor beads, anti-rabbit IgG-coated
acceptor beads, alpha-buﬀer and 384-well Optiplates were
purchased from Perkin-Elmer Life Sciences (Waltham, MA,
USA). Glutathione–agarose beads, thrombin, epidermal growth
factor (EGF), vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF) and hemoglobin were
obtained from Sigma-Aldrich (St. Louis, MO, USA). Bilirubin,
triglyceride and ascorbic acid were purchased from Aladdin
Industrial Corporation (Shanghai, China). BCA™ Protein Assay
Kit was purchased from Thermo Fisher Scientic Inc. (Wal-
tham, MA, USA). Other reagents were obtained from Sigma-
Aldrich (St. Louis, MO, USA) and Aladdin Industrial Corpora-
tion (Shanghai, China). Ultrapure water was produced by
a Milli-Q Reagent Water System (Millipore, MA, USA).2.2 Preparation and certication of reference standard of
NHERF1 proteins
The glutathione-S-transferase (GST)-tagged NHERF1 expression
plasmid pGEX-GST-NHERF1 was kindly provided by Dr Jiale
Dai, MD Anderson Cancer Center, Houston, TX. The methods
for expression fusion proteins were used as previously
described.24 GST-NHERF1 protein was puried with gluta-
thione–agarose beads according to the manufacturer's instruc-
tions. GST tag was excised by thrombin. GST was removed by
glutathione–agarose beads.
Proteins were analyzed by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS/PAGE) and visualized by
Coomassie blue staining. Protein bands of interest were excised
from Coomassie blue-stained gels, cut into small pieces,
washed three times with the wash buﬀer [25 mmol ammonium
bicarbonate in 50% ACN (pH 8.0)], and vortexed for 15 min. The
samples were then reduced and alkylated by treatment with
dithiothreitol (DTT, 10 mmol) and iodoacetamide (55 mmol),
respectively. The gel pieces were then subjected to in-gel
digestion, as described previously.25 Tryptic peptides wereRSC Adv., 2015, 5, 84164–84171 | 84165
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View Article Onlineanalyzed by prOTOF 2000 matrix-assisted laser desorption/
ionization orthogonal time-of ightmass spectrometry (MS)
(Perkin-Elmer, Shelton, CT, USA) interfaced with the TOFWorks
soware (Perkin-Elmer, Shelton, CT, USA). In this study, a two-
point external calibration of the prOTOF instrument was per-
formed before acquiring the spectra of the samples. The protein
was analyzed by searching Oryctolagus cuniculus sequences in
the SWISS-PROT database using Aldente, a peptide mass
ngerprinting tool.26
Protein concentrations were determined with a BCA™
Protein Assay Kit using bovine serum albumin (BSA) as a stan-
dard according to the manufacturer's protocol.
2.3 AlphaLISA assay
The AlphaLISA assay was performed in AlphaLISA buﬀer with
a nal reaction volume of 50 mL in 384 well microplate at room
temperature. Briey, the test samples and standards (5 mL) were
added into the 384-well plates. An aliquot of 10 mL mix solution
of anti-NHERF1 mouse antibody (nal concentration 10 mmol)
and anti-NHERF1 rabbit antibody (nal concentration 50
mmol) in the assay buﬀer was added into the wells. The plates
were covered with a lid and incubated at 37 C for 60 min.
Subsequently, anliquots of 10 mL of anti-rabbit IgG-coated
acceptor beads (nal concentration 10 mg mL1) in assay
buﬀer were added and incubated at 37 C for 60 min. Finally,
anliquots of 25 mL of anti-mouse IgG-coated donor beads (nal
concentration 10 mg mL1) were added and the plate incubated
at room temperature for 30 min in the dark. The AlphaLISA
signal was measured on a 2104 EnVision Multilabel Reader
(Perkin-Elmer Life Sciences, MA, USA).
2.4 Method validation
2.4.1 Linearity and range. For calibration purposes, a series
of standard solutions were developed by diluting reference
standard NHERF1 proteins in AlphaLISA buﬀer. This step
generated the desired standard concentrations of 5.00, 10.0,
20.0, 50.0, and 100 ng mL1. All the standard solutions were
stored at 4 C until analysis.
2.4.2 LOD & LOQ. The limits of sensitivity of the assay were
measured using the limit of detection (LOD) and the limit of
quantication (LOQ). The limit of detection (LOD) is the
concentration of the proteins required to give a signal equal to
the background (blank) plus three times the standard deviation
of the blank; the lower limit of quantication (LLOQ) is twice
the level of the LOD or the point where the CV falls below 20%,
whichever is highest. The upper limit of quantication (ULOQ)
is the point at which the calculated precision does not exceed
15% of the CV and the accuracy is within 15% of the expected
concentration.
2.4.3 Precision. To determine the precision of the micro-
array platform, intra- and inter-assay comparisons were per-
formed for the reference standard NHERF1 with a range of 5.00–
100 ng mL1 and three plasma samples of patients with the
diﬀerent concentrations of NHERF1 15.2, 22.0 and 62.9 ng
mL1, respectively. For the intra-assay (within-assay, within-
plate) study, three duplicates of each sample were placed84166 | RSC Adv., 2015, 5, 84164–84171randomly on the same plate and analyzed in the same test. The
intra-assay variation was calculated from the variation of the
eight determinations of NHERF1 concentrations. For the inter-
assay study (between plates, between runs), we assessed the
variation by analyzing samples in the same manner in eight
independent tests, one duplicate per day, and each sample in
a diﬀerent position on the plate in each test.
2.4.4 Recovery. Spiking recovery was assessed by adding
nal exogenous NHERF1 concentrations of 10.0, 40.0 and 80.0
ng mL1 to three plasma samples from diﬀerent patients. The
concentrations of plasma NHERF1 in these three patients were
14.2, 33.3 and 46.2 ng mL1, respectively.
Ten microliters of each of the exogenous NHERF1 protein
was spiked into 190 mL of plasma samples at a ratio of 1 : 19,
leaving the plasma matrix of the spiked sample relatively intact.
To calculate the expected values, 95% of the unspiked value was
added to 5% of the spiking solution concentration. Evaluations
were performed by calculating the ratio between measured and
expected values.
2.4.5 Selectivity. To investigate the selectivity of the devel-
oped NHERF1 assay, the eﬀect of adding other growth factor
proteins, frequently measured in plasma, epidermal growth
factor (EGF), vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF) to normal human plasma
samples was assessed. The cross-reactivity was expressed as the
percent ratio between measured and expected values.
2.4.6 Interferences. Interference was assessed by the addi-
tion of interfering substances to plasma samples at the stated
nal concentrations as follows: hemoglobin from washed
hemolyzed erythrocytes, bilirubin (unconjugated) prepared in
sodium carbonate/dimethyl sulfoxide, and triglyceride in the
form of intralipid 20% fat emulsion, and sodium ascorbate.2.5 Method application
Clinical plasma samples (n ¼ 93) were collected from Xuanwu
Hospital (Beijing, China). The clinical plasma samples included
75 patients with non-small cell lung cancer (NSCLC) (18 lung
squamous cell carcinoma, 34 lung adenocarcinoma, 3 adenos-
quamous carcinoma and 20 unclear type NSCLC), and 18
healthy donors. Venous blood samples were collected in sterile
vacationers with EDTA anticoagulant. Plasma samples were
immediately separated from the anti-coagulated whole blood by
centrifugation at 3000g for 15 min at 4 C. Samples were stored
at 20 C for 2 months before analysis. The Ethical Committee
of Science and Technology Department of Xuanwu hospital
approved the collection of these samples.2.6 Statistical analysis
The data were expressed as mean values from duplicate
measurements. The data were analyzed with GraphPad Prism 5
soware version 5.03 (GraphPad Soware Inc., La Jolla, CA,
USA), and other statistical analyses were performed using SPSS
soware (version 16.0, SPSS Inc., Chicago, IL, USA). Results
were analyzed by the Mann–Whitney U-test. A p-value of <0.05
was considered statistically signicant.This journal is © The Royal Society of Chemistry 2015
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View Article OnlineThe overall diagnostic performance of NHERF1 was assessed
by the use of receiver operating characteristic (ROC) curves
constructed using plasma from healthy donors and patients
with lung cancer. The cut-oﬀ value of the test was calculated
using the results of the ROC curve distribution, which was
based on a combination of good sensitivity with high specicity.
The area under the curve (AUC) for NHERF1 was determined
using SPSS soware (version 16.0, SPSS Inc., Chicago, IL, USA).
The AUC is a summary statistic of overall diagnostic perfor-
mance. The closer the AUC is to a value of one, the higher the
diagnostic value of the test.3. Results
3.1 Identication of NHERF1 pure protein
GST fusion NHERF1 protein was expressed in E. coli (BL21) and
puried by means of GST aﬃnity chromatography (Fig. 2a).
NHERF1 was excised by thrombin. Aer the GST protein was
removed by aﬃnity to glutathione–agarose beads, NHERF1
protein was collected in the supernatant. Protein concentration
was 3.95 mg mL1 determined with a Bio-Rad Protein Assay Kit
using BSA as a standard.Fig. 2 NHERF1 protein puriﬁed by GST aﬃnity chromatography (a) Comm
step of the chromatographic puriﬁcation procedure. (M), precision plus p
coli BL21 without induction with IPTG; (lane 2) homogenates of E. coli B
puriﬁed GST-NHERF1 protein by GST aﬃnity chromatography; (lane 4) tot
NHERF1 protein identiﬁed by MS analysis. The bands of puriﬁed NHERF
matrix assisted laser desorption/ionization orthogonal time-of ﬂight MS.
This journal is © The Royal Society of Chemistry 2015Samples from each step (total ve steps) of the purication
procedure were applied to SDS/PAGE, and proteins were visu-
alized by Coomassie blue staining. The puried protein from
step ve of the purication gave only one band at a molecular
mass of 50 kDa, indicating a single polypeptide of the 50 kDa
protein (Fig. 2a). The band of puried NHERF1 was excised
from the Coomassie blue-stained gel and identied by matrix
assisted laser desorption/ionization orthogonal time-of ight
MS (Fig. 2b).
3.2 Establishment of assay conditions
To establish assay conditions, dose-response curves of anti-
NHERF1 antibodies were generated. Anti-NHERF1 antibodies
were prepared in AlphaLISA buﬀer and serially diluted. Dose-
response curves of anti-NHERF1 rabbit antibodies were gener-
ated by adding 5–100 mmol anti-NHERF1 rabbit antibody with
anti-NHERF1 mouse antibody ranged from 5 to 100 mmol
respectively in nal 50 mL AlphaLISA reactions. Anti-rabbit IgG-
conjugated acceptor beads and anti-mouse IgG-conjugated
donor beads both were used at 10 mg mL1 in AlphaLISA reac-
tions. The dose-response curves were performed in 5 mL of
human plasma sample. For the dose-response curves, the peakassie-blue-stained SDS-polyacrylamide gels showmaterial from each
rotein standards (Bio-Rad, California, USA). (Lane 1) homogenates of E.
L21, expressing GST fusion NHERF1 protein induced by IPTG; (lane 3)
al protein after thrombin digestion; (lane 5) puriﬁed NHERF1 protein. (b)
1 were excised from the coomassie blue-stained gel and identiﬁed by
The 50 kDa band was identiﬁed as NHERF1.
RSC Adv., 2015, 5, 84164–84171 | 84167
Fig. 3 Eﬀect of anti-NHERF1 mouse (mo) and rabbit (ra) antibody
concentration on AlphaLISA signal. 5–100 mmol anti-NHERF1 rabbit
antibody was incubated with anti-NHERF1 mouse antibody (ﬁnal from
5 to 100 mmol) and 10 mg mL1 acceptor beads and 10 mg mL1 donor
beads in ﬁnal 50 mL AlphaLISA reactions. The dose-response curves
were performed in 5 mL of human plasma sample. The binding is dose
dependent until the hook point is reached.
Table 1 Intra- and inter-assay precision of the AlphaLISA assay
Intra-assay Inter-assay
Concentration
(ng mL1) RSD (%)
Concentration
(ng mL1) RSD (%)
Standard NHERF1 sample
1 5.11  0.24 4.72 5.10  0.26 5.17
2 10.4  0.40 3.80 9.94  0.61 6.18
3 20.4  0.48 2.36 19.8  0.48 2.44
4 49.9  1.71 3.43 50.0  1.08 2.16
5 100.4  2.13 2.12 100.2  2.24 2.23
Plasma sample
2-C1 15.2  0.55 3.62 15.0  0.62 4.12
1-D9 22.0  0.40 1.83 22.5  0.57 2.55
3-F7 62.9  1.71 2.73 62.6  1.90 3.03
Table 2 Analytical recovery of NHERF1 added to plasma samples
Originala
(ng mL1)
Addedb
(ng mL1)
Expected NHERF1
(ng mL1)
Measured NHERF1
(ng mL1)
Recovery
(%)
14.2 10 14.0 13.6 97.3
40 15.5 14.8 95.7
80 17.5 17.3 99.1
33.3 10 32.1 32.9 102.5
40 33.6 33.3 98.9
80 35.6 34.0 95.5
46.2 10 44.4 41.8 94.3
40 45.9 43.8 95.4
80 47.9 50.2 104.8
a The volume of original plasma was 190 mL. b The volume of added
exogenous NHERF1 was 10 mL.
Table 3 Selectivity of the AlphaLISA assay
Antigens
Concentration
(ng mL1)
NHERF1
Value
(ng mL1)
Cross
reactivity rate (%)
EGF (ng mL1) 1000 1.47 0.15
PDGF (ng mL1) 100 0.57 0.57
VEGF (ng mL1) 250 0.25 0.10
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View Article Onlineof AlphaLISA counts appeared at 50 mmol anti-NHERF1 rabbit
antibody and 10 mmol anti-NHERF1 mouse antibody. Hence,
50 mmol anti-NHERF1 rabbit antibody was nally chose to be
used with 10 mmol anti-NHERF1 mouse antibody in the
AlphaLISA reactions (Fig. 3).
3.3 Method validation
3.3.1 Calibration curve, LOD and LOQ. A NHERF1 linear-
ized standard curve (Y¼ 32.2X + 70.8, R2¼ 0.9983) was obtained
with ve concentrations. The standard curve possessed an
intensity range between 218 and 3325 signal counts from 5.00 to
100 ng mL1. The LOD and LOQ values were determined to be
2.00 ng mL1 and 5.00 ng mL1, respectively. The upper limit of
quantication (ULOQ) value was calculated to be 100 ng mL1.
3.3.2 Precision. To ascertain the precision of the AlphaLISA
assay, two experiments were performed. In the rst experiment,
precision was assessed by performing a number of duplicate
tests of the reference standard NHERF1 with a range of 5.00–100
ng mL1. The intra-assay RSD% was from 2.12% to 4.72%. The
inter-assay RSD% was from 2.16% to 6.18%. While in the
second experiment, precision was assessed by performing of
three plasma samples. The intra-assay RSD%was from 1.83% to
3.62% and the inter-assay RSD% was from 2.55% to 4.12%
(Table 1).
3.3.3 Recovery. The spike-in experiments were performed
to ascertain the recovery of the present AlphaLISA assay,
because NHERF1 is a scaﬀold protein naturally existing in
human plasma. The exogenous NHERF1 with three concentra-
tion levels of 10.0, 40.0 and 80.0 ng mL1 were added to three
aliquots of human plasma samples with NHERF1 at three
concentrations (14.2, 33.3 and 46.2 ng mL1), respectively.
Evaluations were then made by calculating the ratio between
measured and expected values of NHERF1. The percentage
recovery of NHERF1 was between 94.3% and 104.8% (Table 2),
suggesting that recovery of the diﬀerent plasma samples was
quantitative and that NHERF1 was accurately measured in the
real samples.84168 | RSC Adv., 2015, 5, 84164–841713.3.4 Selectivity. To investigate the selectivity of the devel-
oped NHERF1 assay, the eﬀect of adding other growth factor
proteins, frequently measured in plasma, epidermal growth
factor (EGF), vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF) to normal human plasma
samples was assessed. The cross-reactivity was expressed as the
percent ratio between measured and expected values. Results in
Table 3 show that no major cross-reactivity was identied
among the compounds.
3.3.5 Interference. The eﬀect of hemolysis, lipemia and
bilirubinemia was assessed by adding hemolysate, bilirubinThis journal is © The Royal Society of Chemistry 2015
Table 4 Interference from addition of hemolysate, bilirubin, triglyc-
eride, and ascorbic acid to patients plasma samples
Interfering substance
AlphaLISA counts of NHERF1
Recovery
(%)
Interfering
substance
Plasma
sample
Spike-in
sample
200 ng mL1 hemoglobin 120 1732 1642 94.8
50 ng mL1 bilirubin 123 1036 934 90.2
1000 ng mL1 triglyceride 121 1381 1481 107.2
200 ng mL1 ascorbic acid 112 751 811 108.0
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View Article Online(unconjugated), triglyceride and sodium ascorbate to the
plasma samples. The recoveries of NHERF1 in these samples
were calculated from the AlphaLISA counts of NHERF1Fig. 4 Contents of NHERF1 were evaluated in plasma obtained from
75 NSCLC patients and 18 healthy donors by AlphaLISA. (a) NHERF1
protein levels are increased in lung cancer patient plasma. NHERF1
protein levels were analyzed by AlphaLISA, as described in Materials
and methods. Grouped data indicate a signiﬁcant increase in the
median value of patient NHERF1 expression in lung cancer patient
plasma with respect to the median value found in the healthy donors.
(b) Receiver operating characteristic (ROC) curve of the concentration
of NHERF1 in plasma to predict precursors of patients with lung
cancer. The area under the ROC curve was 0.728. The cut-oﬀ value for
the detection of lung cancer was 19.9 ng mL1 with 77.3% sensitivity
and 66.7% speciﬁcity.
This journal is © The Royal Society of Chemistry 2015determined before and aer addition of interfering substances.
The recoveries were between 90.2% and 108.0% (Table 4).3.4 AlphaLISA assay
To determine clinical signicance of NHERF1 contents in
plasma for diagnosis of NSCLC, we evaluated contents of
NHERF1 in plasma obtained from 75 NSCLC patients and 18
healthy donors by AlphaLISA. Means of contents for NHERF1 in
the plasma of cancer patients and healthy donors were 31 (SD
16) and 22 (SD 7), respectively. The levels of NHERF1 protein in
plasma from patients were signicantly higher than those in the
healthy group (p ¼ 0.0004) (Fig. 4a).
ROC curves with corresponding AUR for NHERF1 contents in
plasma from cancer vs. control cases are shown in Fig. 4b. Based
on the evaluation of the ROC curves for NHERF1, the optimal
cut-oﬀ was 19.9 ng mL1, and the corresponding sensitivity and
specicity were calculated. Based on the cut oﬀ, NHERF1
increased level was found in 58 of 75 and 6 of 18 control
samples from cancer patients and healthy donors, resulting in
77.3% sensitivity and 66.7% specicity in the diagnosis of lung
cancer. The data suggested that measuring contents of NHERF1
could provide a potential diagnostic tool for NSCLC.4. Discussion
As a high sensitivity homogeneous immunoassay with wide
dynamic range and robust performance, AlphaLISA has been
successfully applied to the detection of soluble proteins and
particular antigens.20,22,23 In this study, a 384-well plate-based
homogeneous chemiluminescent sandwich immunoassay has
been established for the quantication of NHERF1 in human
plasma. During the period of the design of the assay, the
AlphaLISA kit with streptavidin-coated donor beads and anti-
rabbit IgG-coated acceptor beads was rstly selected for the
assay according to the published literatures.18,20 One
biotinylated-antibody and another rabbit derived antibody
recognizing and binding to NHERF1 protein in no cross peptide
segment were required to support the use of the kit in the
AlphaLISA reactions. However, the biotinylated NHERF1 anti-
bodies were not easily to obtain, thus the assay program had to
been adjusted. As shown in Fig. 1, the samples were incubated
with one anti-NHERF1 rabbit antibody (recognizing 128–249 aa)
and another anti-NHERF1 mouse monoclonal antibody (recog-
nizing 310 aa). The kit contains anti-mouse IgG-coated donor
beads and anti-rabbit IgG-coated acceptor beads. The resulting
complex was formed between acceptor beads and NHERF1
rabbit antibody–analyte–NHERF1 mouse antibody–donor
beads, and was quantied in the well by excitation of the donor
beads with laser irradiation at 680 nm. The specic delayed
sharp chemiluminescent emission peak was monitored at
about 615 nm. It was indicated that this kind of sandwich
immunoassay enables the quantication of free NHERF1 in the
plasma using the relatively cheaper and easily obtained
reagents without any treatment. The adjusted and improved
AlphaLISA protocol in the present assay could be used not onlyRSC Adv., 2015, 5, 84164–84171 | 84169
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View Article Onlinefor the detection of NHERF1 protein but also other proteins in
plasma, which makes the technology more versatile.
Identication of assays that are easy-to-use, sensitive, and
precise, while oﬀering lower labor and material costs and
increased throughput and productivity, is a common goal
among researchers conducting drug discovery, preclinical
studies, and basic research. AlphaLISA technology has the
ability to run large numbers of samples using a small sample
volume in a homogeneous environment, while providing
excellent sensitivity and an expanded dynamic range relative to
ELISAs. These assays allow increasing throughput while
decreasing hands-on and total assay time when compared to
standard ELISA protocols. The assay can be handled manually
or as an automatic setup, which facilitates assay development
and makes the technology more versatile.
NHERF1-AlphaLISA assay is very sensitive with a detection
limit of 2.00 ng mL1, which allows the measurement of low
concentrations of NHERF1. The higher sensitivity was obtained
because of the amplied signal resulting from the 60 000 singlet
oxygen molecules generated by each donor bead. At these low
signal levels, an assay may generate false results because of
interference. However, the assay was found to be robust to
plasma interference. Thus, the accuracy, even at very low
concentrations of NHERF1, should be acceptable and robust.
Homogenous assay systems are potentially more sensitive to
plasma interference. The most prominent types of general
interference are inner lter eﬀects and singlet oxygen
quenchers. By using Eu complex in the acceptor beads emitting
light at 615 nm, the inner lter eﬀects are minimal when testing
plasma. Ascorbic acid and heme iron are the main potential
singlet oxygen quenchers in plasma. However, our results
indicated that the assay was unaﬀected by interfering
substances including hemolysate, bilirubin, triglyceride, and
ascorbic acid at concentrations that might be expected in
a routine clinical laboratory setting. In addition, cross-reactivity
data with major interfering protein factors in plasma showed
the assay was highly specic for NHERF1.
Data from a number of laboratories have clearly shown that
increased NHERF1 expression in the primary tumor is of clin-
ical signicance,12,27–29 in that NHERF1 expression is increased
in tumors as compared with the contiguous non-involved
tissue,28,30 and the relative level of increased NHERF1 protein
is signicantly associated with a more aggressive phenotype
and a poor prognosis. Recent epidemiological, preclinical and
clinical studies have suggests that the biomarker in plasma is of
biological and clinical importance for patients with cancer.
According to the record in GeneCards database, the content of
NHERF1 is about 33 ppm in human plasma detected by Spectral
counting. However, no studies have reported the method for the
measurement of plasma NHERF1 and the changes of NHERF1
in plasma correlated with cancer. For this reason, we analyzed
the level of NHERF1 by AlphaLISA in the plasma of those of
NSCLC and healthy donors. We observed that NHERF1 is
indeed more highly over-expressed in plasma of patients with
lung cancer compared with healthy donors. These data are in
line with the recent study on the expression of NHERF1 in the
cancer and paraneoplastic tissue. For example, NHERF1 is84170 | RSC Adv., 2015, 5, 84164–84171reported highly over-expressed in breast14 and colon tumor
tissues13 and this over-expression is associated with increasingly
aggressive clinical characteristics and with poor prognosis.13,15
Unfortunately, there is still no report about the expression of
NHERF1 in the tissues of lung cancer and their relevance to
clinical outcome. To identify the expression of NHERF1 in lung
cancer, we analyzed the gene expression in the TCGA database.
Results showed NHERF1 expression was signicantly increased
in lung adenocarcinoma tissues when compared with the
normal tissues of patients in TCGA dataset (ESI†). This result
was consistent with the contents of NHERF1 in plasma of
patients with NSCLC. These data indicate that NHERF1
expression could represent a new prognostic factor in patients
with NSCLC. The relationships between these ndings and the
risk of lung cancer need further investigation.5. Conclusion
In this study, a novel AlphaLISA assay was developed to quantify
NHERF1 in human plasma. The favorable performance char-
acteristics of NHERF1-AlphaLISA assay including no radioactive
waste, relatively simple and rapid operation within 3 h, low
costs with 5 mL samples for each reaction, high-throughput
assay with 384 samples quantied in one batch, high sensi-
tivity with low LOD of 2.00 ng mL1 and a wide linear range with
from 5.00 to 100 ng mL1. Therefore, the NHERF1-AlphaLISA
assay may be considered as a model system to measure the
tumor maker in biological samples for biomedical studies and
clinical examination. Moreover, our results conrm the
involvement of NHERF1 in plasma associated with neoplastic
diseases. The measurement of NHERF1 levels in plasma has the
potential to extend the use of NHERF1 as tumor biomarker in
NSCLC, supporting the TCGA dataset data. Although the 77.3%
sensitivity and 66.7% specicity are still not yet eﬃcient for
routine clinical application, the detection of NHERF1 content in
plasma seems still to be a promising biomarker in the detection
of NSCLC. The result might indicate the need to develop
a strategy for simultaneous assessment of a panel of tumor-
specic biomarkers in plasma for highly sensitive and specic
diagnosis of lung cancer. More studies about NHERF1 in
plasma associated with neoplastic diseases need investigation,
for example, the relationship between NHERF1 contents in
plasma and clinic-pathological factors such as histological
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